Digital & AI Development Tracker: A Data-Driven View of Manufacturing’s Next Competitive Layer

During the past several years, AI use in pharma has expanded well beyond molecule discovery. The strongest momentum is now appearing in the operational core of the industry: process development, manufacturing execution, quality systems, and supply chain. Industry analysis indicates that AI applications could create between $350 billion and $410 billion in annual value for pharma this year alone, with manufacturing and supply chain among the most impacted functions.

This shift is occurring alongside a broader push toward digital manufacturing. FounderNest data show that digital twins and virtual manufacturing are among the fastest-growing AI technology segments, while manufacturing execution systems (MES) represent the largest process area for AI adoption over the last year.

For pharma, the question is no longer whether AI will reach manufacturing, but how quickly companies can translate digital capabilities into durable process advantage.

Patent Clusters Show Where Innovation Is Concentrating

Our patent analysis has identified three dominant innovation clusters duirng the last five years:

• Continuous manufacturing and automated flow chemistry
• AI-driven synthesis and laboratory automation
• Advanced formulation science, including polymorph and particle engineering

These clusters are increasingly converging. Continuous manufacturing relies on enhanced monitoring and control; AI-driven synthesis platforms are extending from route design into lab execution and process optimization; and formulation development is becoming more model-driven, reducing empirical iteration during scale-up.

Our data also show that AI and digital twins are now being embedded directly into manufacturing systems. Examples include:

• Digital process twins combining simulation with ML-based “soft sensors” to estimate critical quality attributes in real time
• Event-driven control systems integrating live process data into automated decision loops
• AI-assisted and AR-enabled batch record systems that streamline QA documentation

The broader implication is clear: process intelligence itself is becoming patentable infrastructure.

Growth in AI-Related Pharma Patents Remains Strong

FounderNest data, incorporating GlobalData analysis, show that AI-related pharma patent filings grew at approximately 23% CAGR between 2020 and 2022 and remained highly active through 2024.

In Q3 2024 alone, there were 194 AI-related pharma patent applications, with the US accounting for 35%, China for 20%, and Japan for 6%.

Taken together with FounderNest’s process-focused tracking, this points to sustained expansion in:

• AI-enabled process development
• Continuous and flow-based manufacturing
• Digital twins and hybrid modelling
• Advanced formulation technologies

Geographically, our data show the US leading in AI integration and automation platforms, Europe in bioprocess modelling and robotics, and China in scaling manufacturing automation infrastructure.

Emerging Companies Are Defining the Commercial Layer

A representative set of growth-stage highlights a clear shift: emerging players are increasingly embedded within GxP manufacturing workflows, rather than operating as external analytics tools.

Aizon focuses on AI-powered GxP manufacturing, including electronic batch records and predictive optimization. Apprentice.io has built an AI-enabled manufacturing cloud combining MES, LES, and eLogs for batch-based manufacturing. DataHow, an ETH Zurich spin-out, applies hybrid mechanistic-ML models and digital twins to bioprocess development and scale-up. Leucine is building an AI-driven compliance layer around shop-floor operations, while Mareana focuses on continued process verification and QA/QC analytics. Tulip Interfaces, an MIT spin-out, has become increasingly relevant in regulated manufacturing through no-code frontline applications, computer-vision QC, and AI-enabled shop-floor orchestration.

These companies are notable because they are not just offering analytics overlays. Increasingly, they sit inside the execution layer of manufacturing and quality operations, making them strategically important once deployed at scale.

Pharma and CDMOs Are Accelerating Adoption

Large pharma companies are increasingly treating AI and digital manufacturing as infrastructure rather than pilot projects. Sanofi has publicly linked AI to manufacturing and supply-chain transformation, including its EVolutive Facilities program built around virtual twins. Roche appears among the more active companies in AI-related pharma patenting, including applications relevant to biomanufacturing. Pfizer, AstraZeneca, Lilly, and others also appear repeatedly in case studies around digital process optimization and continuous manufacturing.

In QA/QC, the practical impact is becoming easier to quantify. Case studies describe Merck using AI to identify process deviations and improve batch consistency, while Amgen’s validated AI-based visual inspection system reportedly increased particle detection by around 70% and reduced false rejects by about 60%. Other quality-system case studies report 50–60% reductions in investigation time and meaningful improvements in deviation management.

CDMOs are also becoming key adoption channels. Market analyses now describe an emerging AI-integrated CDMO process-optimization segment, with digital twins and virtual manufacturing as the fastest-growing AI technology type and MES the largest process area by market share in 2024. Leading CDMOs, including Thermo Fisher, Lonza, Catalent, WuXi Biologics, and Samsung Biologics, are increasingly framing digital automation, real-time monitoring, and predictive optimization as differentiating capabilities.

Strategic Implications

Three conclusions stand out.

1. Digital twins and hybrid models are transitioning from pilots to core infrastructure across process development, tech transfer, and manufacturing design.
2. Process-level IP is becoming more strategic, as AI is embedded into synthesis, formulation, and control systems.
3. Data readiness remains the primary constraint, with persistent challenges around silos, legacy systems, fragmented batch records, and model governance.

Looking Ahead

Our analysis indicates that pharmaceutical manufacturing is entering a phase in which digital process capability may matter as much as physical scale. The next competitive divide is likely to emerge between companies that treat AI as a local productivity tool and those that build it into long-term process intelligence infrastructure.

For organizations tracking the next wave of manufacturing advantage, patent signals, startup activity, and CDMO adoption all point in the same direction: AI and digital tools are no longer peripheral to development and manufacturing. They are becoming part of the competitive architecture.

For access to the full data, set please visit here.